Order-of-magnitude gap: the company is already serving a demand source whose scale dwarfs its own current business
The model's full reasoning — Q3 2016 call → NOWe need to determine if management describes a mismatch of scale between the company and the demand it is already serving. The key is: the company is already inside a large flow, and management explicitly draws the size contrast, treating it as the point. Looking at the transcript, the main discussion is about the oil and gas acquisition in the Anadarko basin (the "stack" play). Jason O'Connell describes the acquisition: buying royalties for $100 million. He mentions the current annualized revenue is $3 million, but expects significant growth. He says: "The stack is an emerging play and drilling is only recently begun on royalty lands." He also says: "we're investing early in a play that we believe has excellent growth potential and therefore royalty revenues are expected to ramp up significantly in the coming years." He mentions that there are about 25 producing wells, and about 45 drilled but not yet paying. He says: "we expect as those wells come online over the course of the next few months and hits pay status, our revenue will increased significantly." He also says: "if those wells continue to drill on royalty lands for the course of the year they would add roughly $4.5 million in revenue in that first year." That's from three rigs. So the current revenue is $3 million, and they expect to add $4.5 million from those rigs, so roughly $7.5 million annualized? But that's still small relative to the company's overall revenue (which is in hundreds of millions). The company's total revenue is much larger. So the scale of the opportunity relative to the company? The company is Franco-Nevada, a large royalty company. The $100 million acquisition is a small part of their portfolio. They have $1.5 billion in available capital. So the company is large relative to this acquisition. The question is whether management conveys that the company is already inside something enormous relative to its own size, such that a modest further share would make it several times bigger. Here, the acquisition is a small piece. The company is not small relative to the opportunity. The opportunity is a single play, but the company is a large diversified royalty company. The management does not say that this play will make the company several times bigger. They say revenue will ramp up significantly, but they don't quantify it relative to the company's total.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
HROW · Q4 2021 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript shows management describing Harrow as already inside the large cataract surgery market (4.5–6 million procedures annually) with real, present-tense participation: thousands of customer relationships, shipping north of two million sterile ophthalmic units last year, and touching roughly one million cataract surgeries. They explicitly contrast this scale against 2021 revenues of $72.5 million, noting that even a modest share of the pass-through-eligible market (1 million procedures × premium pricing) would produce “a big number” and drive revenues “more than double” in the near term. They treat the current business as only the “earliest sliver” of what they are already positioned inside, with the binding question being how much of the existing flow they can capture rather than whether the flow exists. This meets both criteria. The answer is YES. The transcript shows management describing Harrow as already inside the large cataract surgery market (4.
WRBY · Q1 2024 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript explicitly states that the company is already inside the optical industry with real business (245 stores serving customers, 83% of stores offering exams, 2.36 million active customers, and growing revenue from glasses, contacts, and exams). Management then draws the size contrast directly, noting that even the longer 900-store target "would still represent a small fraction of the 45,000 optical shops in the U.S." and that over 50% of major metro areas have only one store.
HSTM · Q3 2017 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...**YES** Management describes the company already being inside a much larger flow of activity (the 80 million-person healthcare workforce, of which 4.6 million are in post-acute settings) and explicitly treats the scale mismatch as the central point. They note their strong sales team is already a “steady contributor” to 4.